StockData

NextCure, Inc. (NXTC) stock

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.88+0.18 (+2.76%)

Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%

NextCure free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NextCure's free cash flow for the twelve months ending Dec 31, 2024 was -$41.28M. For fiscal 2024 it was -$41.28M. The highest annual figure on record is $4.93M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$41.28M–
FY2023Dec 31, 2023-$53.79M–
FY2022Dec 31, 2022-$56.00M–
FY2021Dec 31, 2021-$59.64M–
FY2020Dec 31, 2020-$52.09M–
FY2019Dec 31, 2019-$38.99M-891.1%
FY2018Dec 31, 2018$4.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$6.94M–
Q3 FY2024Sep 30, 2024-$11.62M–
Q2 FY2024Jun 30, 2024-$10.08M–
Q1 FY2024Mar 31, 2024-$12.64M–
Q4 FY2023Dec 31, 2023-$10.68M–
Q3 FY2023Sep 30, 2023-$13.06M–
Q2 FY2023Jun 30, 2023-$15.03M–
Q1 FY2023Mar 31, 2023-$15.03M–
Q4 FY2022Dec 31, 2022-$9.81M–
Q3 FY2022Sep 30, 2022-$15.53M–
Q2 FY2022Jun 30, 2022-$14.90M–
Q1 FY2022Mar 31, 2022-$15.75M–
Q4 FY2021Dec 31, 2021-$14.31M–
Q3 FY2021Sep 30, 2021-$13.22M–
Q2 FY2021Jun 30, 2021-$17.44M–
Q1 FY2021Mar 31, 2021-$14.68M–
Q4 FY2020Dec 31, 2020-$7.26M–
Q3 FY2020Sep 30, 2020-$17.55M–
Q2 FY2020Jun 30, 2020-$15.24M–
Q1 FY2020Mar 31, 2020-$12.04M–
Q4 FY2019Dec 31, 2019-$10.81M-152.5%
Q3 FY2019Sep 30, 2019-$8.44M–
Q2 FY2019Jun 30, 2019-$11.74M–
Q1 FY2019Mar 31, 2019-$8.02M–
Q4 FY2018Dec 31, 2018$20.57M–
Q3 FY2018Sep 30, 2018-$5.03M–
Q2 FY2018Jun 30, 2018-$5.35M–
Q1 FY2018Mar 31, 2018-$5.27M–

More NextCure figures

See a number that looks wrong?